

# **SUPPLEMENTAL MATERIAL**

## **EVITA Trial Investigators and Committee Members**

Site Investigators (\*members of the EVITA trial steering committee): \*Dr. Beth L. Abramson, St. Michael's Hospital, Toronto, Ontario, Canada, Dr. Jean-François Baril, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada, \*Dr. Iqbal Bata, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada, Dr. Qiangjun Cai, McFarland Clinic PC, Ames, Iowa, United States, Dr. Daniel Cassavar, ProMedica Toledo Hospital, Toledo, Ohio, United States, Dr. Suresh Chandrasekaran, The Oklahoma Heart Hospital Research Foundation, Oklahoma City, Oklahoma, United States, Dr. Mohamed Chebaclo, Altru Health System, Grand Forks, North Dakota, United States, Dr. Adam Clarke, Valley Regional Hospital, Kentville, Nova Scotia, Canada, Dr. David Cleveland, Penticton Regional Hospital, Penticton, British Columbia, Canada, Dr. Payam Dehghani, Prairie Vascular Research Network, University of Saskatchewan, Regina, Saskatchewan, Canada, Dr. Danielle Dion, CISSS de Chaudière Appalaches site Hôpital St-Georges, Beauce, Québec, Canada, \*Dr. Mark Eisenberg, Jewish General Hospital/McGill University, Montréal, Québec, Canada, Dr. Naim Farhat, North Ohio Research, Elyria, Ohio, United States, Dr. Nancy Fillion, L'Hôtel-Dieu de Québec, Québec, Québec, Canada, Dr. Eve Gillespie, Glacier View Research Institute, Kalispell, Montana, United States, Dr. François R. Grondin, CISSS Chaudière-Appalaches, Hôtel-Dieu de Lévis site, Québec, Canada, Dr. Herbert Haught, Heart Center Research, Huntsville, Alabama, United States, Dr. John Henry, Heart Consultants, Omaha, Nebraska, United States, Dr. Michael Hong, Buffalo Heart Group, Buffalo, New York, United States, Dr. Thao Huynh, Montréal General Hospital, Montréal, Québec, Canada, Dr. Ayman Iskander, SJH Cardiology Associates and St. Joseph's Hospital, Liverpool, New York, United States, Dr. Smadar Kort, Stony Brook University, Stony Brook, New York, United States, Dr. Charles Lambert, Florida Hospital Pepin Heart Institute, Tampa, Florida, United States, Dr. John Larry, Ohio State University, Columbus, Ohio, United States, Dr. Claude Lauzon, CISSS - Chaudière-Appalaches, Thetford Mines, Québec, Canada, Dr. Pedro Lozano, VA Medical Center, Oklahoma City, Oklahoma, United States, \*Dr. Mina Madan, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, Dr. Peter McCullough and Dr. Thomas Anan, Providence Park Hospital, Novi, Michigan, United States, Dr. Shamir R. Mehta, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada, Dr. Wayne Old, Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States, Dr. Michael Peters, Heart Consultants, Omaha, Nebraska, United States, Dr. Nathalie Roy, Centre de santé et de services sociaux de Chicoutimi, Chicoutimi, Québec, Canada, Dr. Manohara Senaratne, Grey Nuns Community Hospital, Edmonton, Alberta, Canada, Dr. Jeffrey Shanes, Consultants in Cardiovascular Medicine, Melrose Park, Illinois, United States, Dr. Satyendra Sharma, St. Boniface General Hospital, Winnipeg, Manitoba, Canada, Dr. Nalin Srivastava, Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States, Dr. Neville Suskin, London Health Sciences Centre, London, Ontario, Canada, Dr. Mohamed Turki, St. Luke's University Hospital, Bethlehem, Pennsylvania, United States, Dr. Andrew Weeks, Norfolk General Hospital, Simcoe, Ontario, Canada, Dr. Brian Wong, Sudbury Regional Hospital, Sudbury, Ontario, Canada. Data and Safety Monitoring Board members: Dr. Jafna Cox (Chair), Dalhousie University, Halifax, Nova Scotia, Canada, Dr. Peter Faris, University of Calgary, Calgary, Alberta, Canada, Dr. Nadia Kahn, University of British Columbia, Vancouver, British Columbia, Canada. Endpoints Evaluation Committee: Dr. Vidal Essebag, Montréal General Hospital, Montréal, Québec, Canada

**Table S1.** Comparison of baseline characteristics between those included in and those excluded from the study.

<b>Baseline Characteristic</b>	<b>Included (N=172)</b>	<b>Excluded (N=130)</b>	<b>% difference or mean difference</b>	<b>95% CI</b>
<b>Age</b>	57.04 (9.12)	52.35 (8.99)	4.69	2.62, 6.77
<b>Sex (Male)</b>	134 (77.91%)	93 (71.54%)	6.37%	-3.56%, 16.30%
<b>Weight</b>	83.95 (17.68)	89.67 (20.83)	-5.71	-10.19, -1.24
<b>BMI</b>	28.52 (5.37)	31.08 (9.33)	0.91	-4.37, -0.76
<b>BDI score</b>	5.81 (5.93)	6.39 (6.20)	-0.57	-1.97, 0.82
<b>Number of cigarettes/day</b>	20.96 (9.02)	22.09 (12.40)	-1.13	-3.67, 1.42
<b>Fagerstrom nicotine dependence test</b>	5.20 (2.07)	5.52 (2.06)	-0.32	-0.80, 0.15
<b>Number of years smoked</b>	37.69 (11.56)	33.56 (11.25)	4.13	1.53, 6.73
<b>Randomized to varenicline</b>	92 (53.49%)	59 (45.38%)	8.10%	-3.25%, 19.45%
<b>Diabetes</b>	27 (15.70%)	32 (24.62%)	-8.92%	-18.10%, 0.27%
<b>Hypertension</b>	75 (43.60%)	74 (56.92%)	-13.32%	-24.60%, -2.03%
<b>Hyperlipidemia</b>	107 (62.21%)	95 (73.08%)	-10.87%	-21.39%, -0.35%
<b>Medications for depression</b>	17 (9.88%)	8 (6.15%)	3.73%	-2.35%, 9.81%
<b>Other smokers at home</b>	71 (41.28%)	55 (42.31%)	-1.03%	-12.27%, 10.21%
<b>Prior MI</b>	31 (18.02%)	22 (16.92%)	1.10%	-7.53%, 9.73%
<b>STEMI</b>	106 (61.63%)	63 (48.46%)	13.17%	1.91%, 24.42%
<b>Previous quit attempts</b>	149 (86.63%)	99 (76.15%)	10.47%	1.56%, 19.39%
<b>Prior use of abstinence aids</b>	94 (54.65%)	56 (43.08%)	11.57%	0.27%, 22.88%
<b>Prior use of varenicline</b>	4 (3.54%)	2 (2.86%)	0.68%	-4.50%, 5.86%
<b>Prior use of bupropion</b>	28 (24.78%)	12 (16.90%)	7.88%	-3.93%, 19.68%
<b>Prior use of NRTs</b>	77 (44.77%)	46 (35.38%)	9.38%	-1.70%, 20.46%

Data are presented as mean (standard deviation) or n (%), as applicable.

Abbreviations: CI = confidence interval; BMI = body mass index; BDI = Beck Depression Inventory; MI = myocardial infarction; STEMI = ST-segment elevation myocardial infarction; NRT = nicotine replacement therapy